Led · Series A · Aug 2026

Boyin Hechuang develops industrial robots that embed embodied AI to continuously interpret environments and derive action sequences for assembly and manipulation tasks. The company introduced the BW10-Lite in December 2025, an 8-kg single-arm robot designed for 24/7 operation and claimed to cover over 60% of certain manual assembly tasks. It is preparing series production in 2026 and plans to release a successor model, BW10, to broaden deployment use cases. Boyin Hechuang is building a specialized data platform to enable robust data collection, labeling and monitoring necessary for industrial learning loops. The startup has formed strategic partnerships with Bosch China and others, and reports letters of intent for customer orders totaling several hundred million U.S. dollars as it seeks commercial validation and repeatable production metrics.

Participated · Series A · May 2026

OriginFlow develops a NeuroScale data-collection paradigm that uses surface electromyography (sEMG) captured by a proprietary EMG acquisition kit and encoded by its PULSE foundation model to reconstruct human intent, hand posture, force magnitude, and multimodal continuous information. Founded in 2025 and operating officially for about five months, the company positions itself as a "picks-and-shovels" provider for embodied AI rather than a robot-body maker. It has optimized hardware design and supply-chain integration to reduce the price of its full data-collection equipment set to roughly 1,000 yuan, lowering barriers for large-scale deployment. OriginFlow is pursuing dataset-building through strategic cooperation with partners such as 58 Group for home-service scenarios and leading manufacturers for industrial settings. Financially, it has raised over 500 million yuan across angel, strategic, and Pre-A1 rounds to scale deployment and model development. The company acknowledges technical and commercial challenges ahead, including validation of engineering generalization in complex real-world scenarios, robustness to electromagnetic interference and non-standard environments, and sustaining a long-term commercial moat beyond one-time hardware sales.

Participated · Series D · Mar 2026

Elite Robots develops a range of robotic products including collaborative robots, composite robots, and humanoid-like machines built on a core VLA+T architecture that fuses vision, language, action, and torque-optimized perception. The company emphasizes full-stack in-house capabilities from operating systems to joint modules, enabling integrated "hand, brain, eye, and foot" agent functionality. Its "one brain, multiple forms" strategy seeks to use a unified agent technology across multiple product form factors. Business performance is described as hyper-growth in group revenue, primarily driven by the composite robotics division, and the company is reported to be among the leaders in profitability in the intelligent robot core systems market. About half of its business relates to AI supply chain activities spanning optical modules, servers, smartphones, smart vehicles, and AI drug discovery. Elite Robots maintains dual headquarters in Suzhou and Zhengzhou and has expanded internationally into Europe, North America, and Southeast Asia with orders from several top-tier global clients.

Participated · Series A · Jan 2026

Startous fusion develops and engineers fusion devices and key reactor technologies, operating a three-generation system that includes the running SUNIST-2 device (in collaboration with Tsinghua University), the under-construction NTST negative-triangle spherical tokamak, and the R&D-stage CTRFR-1. The company is building a Shanghai Jiading experimental base, with the device hall expected to be completed in the second half of 2026 and the full base operational in 2027. NTST’s core components and manufacturing partners have been selected and contracts signed, with installation and commissioning planned for 2026 and operation to rated parameters targeted for 2027. Startous fusion is also advancing fusion-reactor-scale high-temperature superconducting magnet production and AI-driven plasma control as part of its engineering conversion efforts. Financially, the company has raised over ¥2 billion to date, including a ¥1 billion A round in January 2026 led by Shanghai state capital and a ¥500 million A+ round in early 2026 to fund its core engineering and construction milestones.

Participated · Series B · Dec 2025

Sanegene Bio is a biotechnology firm focused on creating RNA interference (RNAi) medicines that target metabolic, cardiovascular, and autoimmune disorders. Its proprietary delivery platform is aimed at improving the clinical utility of RNA-based therapeutics, an area that is experiencing heightened global momentum. The company plans to use its latest capital infusion to advance multiple RNAi programs into registration studies, signaling a move toward late-stage clinical development. Management also intends to broaden the pipeline into additional disease areas within its core therapeutic focus. Although specific revenue or patient enrollment figures were not disclosed, the sizable financing underscores investor confidence in Sanegene Bio’s approach and delivery technology. With substantial strategic backing from industry leaders such as Eli Lilly and repeat participation from prior investors, the company is positioned to accelerate development and expand partnership opportunities.